GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009723712 | Liver | HCC | cellular response to toxic substance | 74/7958 | 124/18723 | 8.36e-05 | 7.36e-04 | 74 |
GO:009875412 | Liver | HCC | detoxification | 87/7958 | 152/18723 | 1.70e-04 | 1.35e-03 | 87 |
GO:009886912 | Liver | HCC | cellular oxidant detoxification | 59/7958 | 101/18723 | 9.00e-04 | 5.31e-03 | 59 |
GO:0006979113 | Thyroid | PTC | response to oxidative stress | 234/5968 | 446/18723 | 6.97e-20 | 9.77e-18 | 234 |
GO:0062197113 | Thyroid | PTC | cellular response to chemical stress | 180/5968 | 337/18723 | 1.36e-16 | 1.16e-14 | 180 |
GO:0034599113 | Thyroid | PTC | cellular response to oxidative stress | 151/5968 | 288/18723 | 2.82e-13 | 1.43e-11 | 151 |
GO:0009636111 | Thyroid | PTC | response to toxic substance | 115/5968 | 262/18723 | 2.70e-05 | 2.63e-04 | 115 |
GO:1990748112 | Thyroid | PTC | cellular detoxification | 56/5968 | 116/18723 | 1.63e-04 | 1.26e-03 | 56 |
GO:0097237112 | Thyroid | PTC | cellular response to toxic substance | 59/5968 | 124/18723 | 1.83e-04 | 1.39e-03 | 59 |
GO:0098869111 | Thyroid | PTC | cellular oxidant detoxification | 49/5968 | 101/18723 | 3.52e-04 | 2.41e-03 | 49 |
GO:0098754110 | Thyroid | PTC | detoxification | 63/5968 | 152/18723 | 7.92e-03 | 3.34e-02 | 63 |
GO:000697934 | Thyroid | ATC | response to oxidative stress | 246/6293 | 446/18723 | 2.98e-21 | 6.09e-19 | 246 |
GO:006219734 | Thyroid | ATC | cellular response to chemical stress | 188/6293 | 337/18723 | 3.16e-17 | 3.07e-15 | 188 |
GO:003459934 | Thyroid | ATC | cellular response to oxidative stress | 158/6293 | 288/18723 | 7.35e-14 | 3.94e-12 | 158 |
GO:000963634 | Thyroid | ATC | response to toxic substance | 119/6293 | 262/18723 | 4.30e-05 | 3.48e-04 | 119 |
GO:199074833 | Thyroid | ATC | cellular detoxification | 58/6293 | 116/18723 | 1.88e-04 | 1.26e-03 | 58 |
GO:009723733 | Thyroid | ATC | cellular response to toxic substance | 61/6293 | 124/18723 | 2.31e-04 | 1.49e-03 | 61 |
GO:009886932 | Thyroid | ATC | cellular oxidant detoxification | 51/6293 | 101/18723 | 3.29e-04 | 2.05e-03 | 51 |
GO:009875433 | Thyroid | ATC | detoxification | 66/6293 | 152/18723 | 7.23e-03 | 2.85e-02 | 66 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa0048018 | Esophagus | ESCC | Glutathione metabolism | 44/4205 | 57/8465 | 1.81e-05 | 9.03e-05 | 4.63e-05 | 44 |
hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa0501638 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa0048019 | Esophagus | ESCC | Glutathione metabolism | 44/4205 | 57/8465 | 1.81e-05 | 9.03e-05 | 4.63e-05 | 44 |
hsa0501614 | Liver | Cirrhotic | Huntington disease | 172/2530 | 306/8465 | 1.65e-22 | 1.10e-20 | 6.77e-21 | 172 |
hsa0501414 | Liver | Cirrhotic | Amyotrophic lateral sclerosis | 187/2530 | 364/8465 | 1.56e-18 | 6.50e-17 | 4.01e-17 | 187 |
hsa0502214 | Liver | Cirrhotic | Pathways of neurodegeneration - multiple diseases | 217/2530 | 476/8465 | 7.30e-14 | 2.03e-12 | 1.25e-12 | 217 |
hsa004809 | Liver | Cirrhotic | Glutathione metabolism | 30/2530 | 57/8465 | 2.63e-04 | 1.72e-03 | 1.06e-03 | 30 |
hsa0501615 | Liver | Cirrhotic | Huntington disease | 172/2530 | 306/8465 | 1.65e-22 | 1.10e-20 | 6.77e-21 | 172 |
hsa0501415 | Liver | Cirrhotic | Amyotrophic lateral sclerosis | 187/2530 | 364/8465 | 1.56e-18 | 6.50e-17 | 4.01e-17 | 187 |
hsa0502215 | Liver | Cirrhotic | Pathways of neurodegeneration - multiple diseases | 217/2530 | 476/8465 | 7.30e-14 | 2.03e-12 | 1.25e-12 | 217 |
hsa0048012 | Liver | Cirrhotic | Glutathione metabolism | 30/2530 | 57/8465 | 2.63e-04 | 1.72e-03 | 1.06e-03 | 30 |
hsa0501622 | Liver | HCC | Huntington disease | 219/4020 | 306/8465 | 3.06e-18 | 3.42e-16 | 1.90e-16 | 219 |
hsa0501422 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
hsa0502222 | Liver | HCC | Pathways of neurodegeneration - multiple diseases | 298/4020 | 476/8465 | 6.59e-12 | 1.30e-10 | 7.22e-11 | 298 |
hsa0048022 | Liver | HCC | Glutathione metabolism | 42/4020 | 57/8465 | 5.00e-05 | 2.62e-04 | 1.46e-04 | 42 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GPX7 | SNV | Missense_Mutation | novel | c.434G>T | p.Trp145Leu | p.W145L | Q96SL4 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
GPX7 | SNV | Missense_Mutation | novel | c.247N>A | p.Ala83Thr | p.A83T | Q96SL4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A62V-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Targeted Molecular therapy | denosumab | PD |
GPX7 | insertion | Frame_Shift_Ins | novel | c.299_300insGGTGTTTGCTAACATGTTTGTATCGTGGTGCATGTGCATACCTA | p.Ile100MetfsTer64 | p.I100Mfs*64 | Q96SL4 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
GPX7 | SNV | Missense_Mutation | novel | c.467N>C | p.Val156Ala | p.V156A | Q96SL4 | protein_coding | deleterious(0.03) | benign(0.296) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
GPX7 | SNV | Missense_Mutation | | c.56C>T | p.Ala19Val | p.A19V | Q96SL4 | protein_coding | tolerated(0.28) | benign(0) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GPX7 | SNV | Missense_Mutation | novel | c.75C>A | p.Phe25Leu | p.F25L | Q96SL4 | protein_coding | tolerated(0.11) | benign(0.325) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GPX7 | SNV | Missense_Mutation | novel | c.128A>C | p.Tyr43Ser | p.Y43S | Q96SL4 | protein_coding | tolerated(0.05) | probably_damaging(0.996) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GPX7 | SNV | Missense_Mutation | novel | c.520N>T | p.Ala174Ser | p.A174S | Q96SL4 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GPX7 | SNV | Missense_Mutation | novel | c.368C>A | p.Thr123Asn | p.T123N | Q96SL4 | protein_coding | tolerated(0.1) | benign(0.005) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
GPX7 | SNV | Missense_Mutation | novel | c.388A>G | p.Lys130Glu | p.K130E | Q96SL4 | protein_coding | deleterious(0.04) | benign(0.181) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |